Literature DB >> 12929941

Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II.

Steven G Waguespack1, Daniel L Koller, Kenneth E White, Tonya Fishburn, Gwenaelle Carn, Kenneth A Buckwalter, Michelle Johnson, Maureen Kocisko, Wayne E Evans, Tatiana Foroud, Michael J Econs.   

Abstract

UNLABELLED: ADO2 is an uncommon sclerosing bone disorder with incomplete penetrance and variable expressivity. Positional candidate studies were performed to identify the gene responsible for ADO2. In 11 of 12 kindreds, five different missense mutations were identified in the ClCN7 gene, indicating the genetic basis and possible dominant negative mechanism for ADO2.
INTRODUCTION: Autosomal dominant osteopetrosis, type II (ADO2) is an uncommon sclerosing bone disorder with a distinct radiographic appearance and unique clinical characteristics. We present the results from our genetic studies designed to identify the ADO2 gene through a positional candidate approach.
METHODS: Having identified 12 families with ADO2, we initially performed linkage studies in our seven largest kindreds and observed a summed maximum LOD score of 15.91 at marker D16S521 on chromosome 16p13.3. Critical meiotic recombination events further narrowed the putative gene region to a 7.6-cM area, which contains the candidate genes ATP6L and chloride channel 7 (ClCN7). We screened affected individuals from each ADO2 family for mutations in these genes using direct sequencing. Identified mutations were subsequently confirmed through direct sequencing or restriction fragment length polymorphism analysis. We then calculated the overall disease penetrance rate after all available at-risk family members were assessed for ClCN7 gene mutations.
RESULTS: No ATP6L mutations were identified in affected subjects. Subsequently, as CICN7 gene mutations were being reported, we identified two novel (L213F, R762L) and three known (G215R, R286W, R767W) missense mutations in 11 kindreds. In our large sample, disease penetrance was 66% (62 clinically affected individuals/94 subjects with the gene mutation). To date, nine different mutations have been discovered in the ClCN7 gene in 22 of 23 ADO2 families studied.
CONCLUSIONS: We conclude that mutations in the CICN7 gene are responsible for ADO2 and that genetic heterogeneity is unlikely to exist in this disorder. Based on the preponderance of missense mutations and the knowledge that chloride channels probably function as dimers, it seems that heterozygous ClCN7 gene mutations may cause ADO2 through a dominant negative mechanism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12929941     DOI: 10.1359/jbmr.2003.18.8.1513

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  30 in total

Review 1.  Regulation of lysosome biogenesis and functions in osteoclasts.

Authors:  Julie Lacombe; Gérard Karsenty; Mathieu Ferron
Journal:  Cell Cycle       Date:  2013-08-05       Impact factor: 4.534

2.  Genotyping, generation and proteomic profiling of the first human autosomal dominant osteopetrosis type II-specific induced pluripotent stem cells.

Authors:  Minglin Ou; Chunhong Li; Donge Tang; Wen Xue; Yong Xu; Peng Zhu; Bo Li; Jiansheng Xie; Jiejing Chen; Weiguo Sui; Lianghong Yin; Yong Dai
Journal:  Stem Cell Res Ther       Date:  2019-08-14       Impact factor: 6.832

3.  Cortical bone quality affectations and their strength impact analysis using holographic interferometry.

Authors:  Cesar G Tavera Ruiz; Manuel H De La Torre-Ibarra; J M Flores-Moreno; Claudio Frausto-Reyes; Fernando Mendoza Santoyo
Journal:  Biomed Opt Express       Date:  2018-09-14       Impact factor: 3.732

4.  Interferon Gamma-1b Does Not Increase Markers of Bone Resorption in Autosomal Dominant Osteopetrosis.

Authors:  Erik A Imel; Ziyue Liu; Dena Acton; Melissa Coffman; Netsanet Gebregziabher; Yan Tong; Michael J Econs
Journal:  J Bone Miner Res       Date:  2019-05-13       Impact factor: 6.741

5.  The virulence gene and clinical phenotypes of osteopetrosis in the Chinese population: six novel mutations of the CLCN7 gene in twelve osteopetrosis families.

Authors:  Chun Wang; Hao Zhang; Jin-Wei He; Jie-Mei Gu; Wei-Wei Hu; Yun-Qiu Hu; Miao Li; Yu-Juan Liu; Wen-Zhen Fu; Hua Yue; Yao-Hua Ke; Zhen-Lin Zhang
Journal:  J Bone Miner Metab       Date:  2011-09-28       Impact factor: 2.626

6.  Novel mutations of CLCN7 cause autosomal dominant osteopetrosis type II (ADO-II) and intermediate autosomal recessive osteopetrosis (IARO) in Chinese patients.

Authors:  Q Pang; Y Chi; Z Zhao; X Xing; M Li; O Wang; Y Jiang; R Liao; Y Sun; J Dong; W Xia
Journal:  Osteoporos Int       Date:  2015-09-22       Impact factor: 4.507

Review 7.  Human Genetics of Sclerosing Bone Disorders.

Authors:  Raphaël De Ridder; Eveline Boudin; Geert Mortier; Wim Van Hul
Journal:  Curr Osteoporos Rep       Date:  2018-06       Impact factor: 5.096

Review 8.  Advances in osteoclast biology resulting from the study of osteopetrotic mutations.

Authors:  T Segovia-Silvestre; A V Neutzsky-Wulff; M G Sorensen; C Christiansen; J Bollerslev; M A Karsdal; K Henriksen
Journal:  Hum Genet       Date:  2008-11-06       Impact factor: 4.132

9.  Identification of the CLCN7 gene mutations in two Chinese families with autosomal dominant osteopetrosis (type II).

Authors:  Zhen-Lin Zhang; Jin-Wei He; Hao Zhang; Wei-Wei Hu; Wen-Zhen Fu; Jie-Mei Gu; Jin-Bo Yu; Gao Gao; Yun-Qiu Hu; Miao Li; Yu-Juan Liu
Journal:  J Bone Miner Metab       Date:  2009-03-14       Impact factor: 2.626

10.  Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II.

Authors:  Kim Henriksen; Jeppe Gram; Sophie Schaller; Bjarne H Dahl; Morten H Dziegiel; Jens Bollerslev; Morten A Karsdal
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.